Pipeline Flex embolisation device with Shield Technology for the treatment of complex
KEYWORDS: pipeline, patients, coiling, cost, stent-assisted coiling, stent-assisted, committee, aneurysms, used, procedure, sponsor, occlusion, costs, use, coils

26 weeks (Fiorella et al. 2009a, 2009b; Sararols et al. 2011). Szikora et al. (2010b) reported resolution of symptoms in 61% of patients at a mean follow-up of 26 weeks. 3.14 Studies of 96, 18, 8 and 5 patients reported subarachnoid haemorrhage after surgery in 1%, 5%, 13% and 20% of patients respectively (absolute figures and follow-up not reported; Hampton et al. 2011; Hartmann et al. 2010; O'Kelly et al. 2011, Szikora et al. 2010b). Committee considerations 3.15 The committee was advised by the experts that Pipeline is currently considered in some specialist units for patients who have symptoms caused by the mass effect of aneurysms, or a high risk of future bleeding, who are considered fit for general anaesthesia and who have an average life expectancy of at least 1 year. 3.16 The committee noted that Pipeline may be the only possible intervention for some patients who have symptoms caused by the mass effect of aneurysms, or a high risk of future bleeding, whose aneurysms are unsuitable for either stent- assisted coiling or surgical treatment and for whom parent vessel occlusion would result in stroke or death. 3.17 The committee considered that data from the studies described above provided
